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Background and hypothesis
Cancer immunotherapies have been advanced by the
recent FDA approval of anti-CTLA-4 antibody (Ipilimu-
mab, Yervoy®) and soon-to-be approved anti-PD-1
antibody, immunological checkpoint-blocking agents with
significant anti-tumor activity against melanoma and other
cancers. A promising avenue to further increase their
efficacy is combination with T cell-inducing vaccination.
Surprisingly, addition of gp100 peptide vaccination did not
increase but actually decreased clinical efficacy to anti-
CTLA-4 in melanoma patients [1]. As a result, it is
currently unclear how to combine anti-CTLA-4 with vac-
cination. We recently reported [2] that vaccination with
gp100 peptide in IFA creates a persisting antigen depot
that primes antigen-specific CD8+ T cells, followed by
their undesirable sequestration at the vaccination site, and
eventually their exhaustion and apoptosis, resulting in
negligible anti-tumor activity. Here, we investigate
whether this phenomenon can also explain the lack
of synergy between IFA-based vaccination and anti-
CTLA-4 therapy.
Results
We found that the inflamed, chemokine-rich vaccination
site potently attracted and sequestered anti-CTLA-4
activated effector T cells with antigen-specificities unre-
lated to the gp100/IFA vaccine. Some of the tumor-
specific T cells induced by anti-CTLA-4 therapy recog-
nized the melanocyte differentiation antigen, TRP-2,
allowing us to quantify their number and localization at
the tumor and vaccination site. Anti-CTLA-4 monother-
apy significantly increased the absolute number of TRP-
2-specific effector T cells at the tumor site at the time of
tumor suppression. Remarkably, gp100/IFA vaccination
induced sequestration at the vaccination site not only of
gp100-specific T cells, but also of TRP-2-specific T cells,
dramatically reducing their numbers at the tumor site. In
addition, gp100/IFA vaccination slightly reduced thera-
peutic efficacy of anti-CTLA-4 therapy, replicating the
reported clinical observation. In contrast, a non-persistent
vaccine formulation, Vesicular Stomatitis Virus encoding
gp100 (VSV.gp100) synergized with anti-CTLA-4 to
enhance anti-tumor activity. Finally, vaccination also
synergized with anti-PD-1 therapy, and with anti-CTLA-4
+ anti-PD-1 combination therapy. Immunohistochemistry
analysis showed co-localization of CD8+ T cells mainly
in ICAM-1 expressing sections of the tumor stroma.
ICAM-1 deficiency in host mice resulted in significant
abrogation of the anti-tumor activity. Similarly, mice trea-
ted with anti-CXCR3 mAb versus control (IgG mAb)
showed significant decrease in survival, which correlated
with decrease in intra-tumoral CD8+ T cell count at
the time of the treatment.
Conclusion
In conclusion, a non-persistent vaccine formulation can
reverse the undesirable effect of the persistent vaccine
formulation and synergizes with anti-CTLA-4 and/or
anti-PD-1 therapies, resulting in significantly improved
anti-tumor activity.
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